Neuphoria Therapeutics (NEUP) Total Current Liabilities (2021 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Total Current Liabilities of $1.5 million for Q1 2026, down 2.5% year-over-year from $1.6 million in Q1 2025, and down 41.49% quarter-over-quarter from $2.6 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Total Current Liabilities (2021 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Total Current Liabilities for 6 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 2.5% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 2.5% YoY), while the FY2025 annual figure was $4.2 million, up 10.23% from the prior year.
- Total Current Liabilities slipped to $1.5 million in Q1 2026 per NEUP's latest filing, from $2.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $5.1 million in Q3 2025 and bottomed at $1.5 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $2.9 million across 5 years, with a median of $2.6 million in 2024.
- Annual changes were most pronounced in 2025 — Total Current Liabilities surged 100.82% — and 2026, when it decreased 2.5%.
- Neuphoria Therapeutics' Total Current Liabilities stood at $2.4 million in 2022, then advanced by 14.83% to $2.8 million in 2023, then declined by 22.69% to $2.1 million in 2024, then increased by 21.21% to $2.6 million in 2025, then plunged by 41.49% to $1.5 million in 2026.
- Business Quant data shows NEUP's Total Current Liabilities at $1.5 million in Q1 2026, $2.6 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 630.93 Mn |
| 10 | Neuphoria Therapeutics | 21.13 Mn | 1.69 Mn | - | 1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Sep 30, 2025 | 5.12 Mn |
| Jun 30, 2025 | 4.22 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 2.55 Mn |
| Jun 30, 2024 | 3.83 Mn |
| Jun 30, 2023 | 2.76 Mn |
| Jun 30, 2022 | 2.40 Mn |
| Jun 30, 2021 | 1.82 Mn |